Neogen Corporation revenue by segment NEOG

Annual Quarterly

Neogen Corporation splits its revenue 2 ways in its filings. By operating segments, the largest line in Q1 of fiscal 2027, the quarter ended Aug 31, 2026 was Food Safety at $163.2 million, 73% of the total. By sales mix, the largest line in Q1 of fiscal 2027, the quarter ended Aug 31, 2026 was Product at $196.0 million, 88% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Aug 31, 2026	Q1 FY2027 Aug 31, 2026	Q4 FY2026 May 31, 2026	Q3 FY2026 Feb 28, 2026	Q2 FY2026 Nov 30, 2025	Q1 FY2026 Aug 31, 2025	Q4 FY2025 May 31, 2025	Q3 FY2025 Feb 28, 2025	Q2 FY2025 Nov 30, 2024
Revenue	884	223	225	211	225	209	226	221	231
Operating segments
Food Safety	652 +3.4% share 73.8%	163 +7.3% share 73.2%	167 +3.1% share 74.0%	157 +2.6% share 74.2%	166 +0.8% share 73.7%	152 share 72.7%	162 share 71.8%	153 share 69.1%	164 share 71.0%
Animal Safety	232 -9.5% share 26.2%	60 +4.4% share 26.8%	58 -8.0% share 26.0%	54 -20.1% share 25.8%	59 -11.8% share 26.3%	57 share 27.3%	64 share 28.2%	68 share 30.9%	67 share 29.0%
Sales mix
Product	—	196 share 88.0%	—	186 -5.2% share 88.2%	—	—	—	196 share 88.9%	208 share 89.7%
Animal Care And Other	—	8 share 3.5%	7 share 3.1%	6 share 2.8%	—	—	—	—	—
Biosecurity Products	—	5 -20.7% share 2.1%	—	4 share 1.8%	—	6 share 2.8%	—	—	12 share 5.2%
Other	—	2 +4.3% share 1.1%	4 -7.7% share 1.6%	4 +20.0% share 1.7%	3 -11.5% share 1.4%	2 share 1.1%	4 share 1.7%	3 share 1.4%	4 share 1.6%
Life Sciences	—	2 -15.8% share 0.7%	2 +12.5% share 0.8%	2 +0.0% share 0.7%	1 -11.0% share 0.6%	2 share 0.9%	2 share 0.7%	2 share 0.7%	2 share 0.7%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: NEOG (Nasdaq)
Fiscal year ends: May 31
Incorporated in: MI
Headquarters: Lansing, MI
SEC filer status: Large accelerated filer
SEC CIK: 711377

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.